Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$24.73

0.74 (3.08%)

06:01
01/10/20
01/10
06:01
01/10/20
06:01

Portola Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Jay Olson downgraded Portola Pharmaceuticals to Perform from Outperform with a price target of $17, down from $40.

  • 14

    Jan

PTLA Portola Pharmaceuticals
$24.73

0.74 (3.08%)

08/05/19
FBCO
08/05/19
INITIATION
Target $35
FBCO
Neutral
Portola Pharmaceuticals assumed with a Neutral at Credit Suisse
Credit Suisse analyst Tiago Fauth assumed coverage of Portola Pharmaceuticals with a Neutral rating and $35 price target.
08/05/19
08/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphatec (ATEC) initiated with an Overweight at Piper Jaffray. 2. So-Young (SY) initiated with a Buy at CLSA. 3. MediWound (MDWD) initiated with a Buy at H.C. Wainwright. 4. Portola Pharmaceuticals (PTLA) assumed with a Neutral at Credit Suisse. 5. Vereit (VER) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/19
SBSH
08/08/19
NO CHANGE
Target $51
SBSH
Buy
The time to buy Portola Pharmaceuticals is now, says Citi
In a post-earnings research note titled "The Time to Buy is Now," Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $51 from $50 and keeps a Buy rating on the shares. The analyst continues to believe Andexxa can be a ~$250M product in 2020 and ~$550M by 2022. Getting to half a billion in sales would require one use per month per hospital, assuming "only" ~1500 active hospitals, which is "very achievable," Nochomovitz tells investors in a research note. This means Portola's fair value is ~$50 per share, not the market view of $27 per share, says the analyst.
11/08/19
GSCO
11/08/19
INITIATION
Target $135
GSCO
Neutral
Portola Pharmaceuticals initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Portola Pharmaceuticals with a Neutral rating and $135 price target. The analyst views the shares as fairy valued as "Andexxa launch execution holds the key."

TODAY'S FREE FLY STORIES

BA

Boeing

$324.11

-7.89 (-2.38%)

14:08
01/20/20
01/20
14:08
01/20/20
14:08
Periodicals
Boeing close to securing $10B loan, Bloomberg reports »

Boeing is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CAE

CAE

$29.65

-0.14 (-0.47%)

14:05
01/20/20
01/20
14:05
01/20/20
14:05
Hot Stocks
CAE appoints Todd Probert as Group President, Defense & Security »

CAE announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ACC

American Campus

$46.31

-0.085 (-0.18%)

14:03
01/20/20
01/20
14:03
01/20/20
14:03
Recommendations
American Campus analyst commentary  »

American Campus announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

UPS

UPS

$118.61

0.005 (0.00%)

14:02
01/20/20
01/20
14:02
01/20/20
14:02
Hot Stocks
UPS launches e-commerce plug-ins as part of UPS Digital Access Program »

UPS announced that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

WINS

Wins Finance

$12.50

-1.2 (-8.76%)

13:58
01/20/20
01/20
13:58
01/20/20
13:58
Hot Stocks
Wins Finance announces submission of compliance plan to Nasdaq »

Wins Finance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$167.06

0.82 (0.49%)

13:55
01/20/20
01/20
13:55
01/20/20
13:55
Recommendations
Microsoft price target raised to $175 from $160 at Stifel »

Stifel analyst Brad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 25

    Feb

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

13:52
01/20/20
01/20
13:52
01/20/20
13:52
Periodicals
Softbank says WeWork still good business at core, Bloomberg reports »

SoftBank (SFTBY;SFTBF)…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EGLE

Eagle Bulk Shipping

$4.25

-0.03 (-0.70%)

13:40
01/20/20
01/20
13:40
01/20/20
13:40
Conference/Events
Eagle Bulk Shipping to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:39
01/20/20
01/20
13:39
01/20/20
13:39
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:38
01/20/20
01/20
13:38
01/20/20
13:38
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

13:35
01/20/20
01/20
13:35
01/20/20
13:35
Downgrade
ConvaTec rating change  »

ConvaTec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
01/20/20
01/20
13:35
01/20/20
13:35
General news
FX Summary: Activity was moribund »

FX Summary: Activity was…

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

13:31
01/20/20
01/20
13:31
01/20/20
13:31
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$182.16

-0.53 (-0.29%)

13:06
01/20/20
01/20
13:06
01/20/20
13:06
Recommendations
BMO keeps 'top pick' status on Salesforce, boosts price target to $210 »

BMO Capital analyst Keith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

SNYYF

Sany Heavy

$0.00

(0.00%)

12:56
01/20/20
01/20
12:56
01/20/20
12:56
Upgrade
Sany Heavy rating change  »

Sany Heavy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATDRY

Auto Trader Group

$0.00

(0.00%)

12:52
01/20/20
01/20
12:52
01/20/20
12:52
Upgrade
Auto Trader Group rating change at Goldman Sachs »

Auto Trader Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIOSF

Atresmedia

$0.00

(0.00%)

12:50
01/20/20
01/20
12:50
01/20/20
12:50
Downgrade
Atresmedia rating change at Goldman Sachs »

Atresmedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGDDF

Lagardere

$0.00

(0.00%)

12:48
01/20/20
01/20
12:48
01/20/20
12:48
Downgrade
Lagardere rating change at Goldman Sachs »

Lagardere downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$66.38

-0.34 (-0.51%)

12:47
01/20/20
01/20
12:47
01/20/20
12:47
Downgrade
WPP rating change at Goldman Sachs »

WPP downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTKWY

Wolters Kluwer

$0.00

(0.00%)

12:46
01/20/20
01/20
12:46
01/20/20
12:46
Downgrade
Wolters Kluwer rating change at Goldman Sachs »

Wolters Kluwer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIOXY

Cielo

$0.00

(0.00%)

12:43
01/20/20
01/20
12:43
01/20/20
12:43
Downgrade
Cielo rating change at Goldman Sachs »

Cielo downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

10:35
01/20/20
01/20
10:35
01/20/20
10:35
General news
Taking an "irrationally bullish" view of U.S. and global stock markets »

Taking an…

09:30
01/20/20
01/20
09:30
01/20/20
09:30
General news
Oil Action: Front-month WTI futures are up 0.7% »

Oil Action: Front-month…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.